This requirement is to perform the release analysis (appearance, PMR, IR, hplc* (assay; impurity), moisture, residual solvents, ROI and heavy metals) of 2 bulk drug lot of NSC 706744. POP is…
Ended Awarded Last action
- Contract number
- 75N91020F00002
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $35,253
Award facts
- Contract value 100% obligated
- $35,252.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$15,863 | |
| Original award | $51,116 |
About this award
The National Cancer Institute issued a $35,252.94 delivery order to Sri International on February 24, 2020, under the NIH Analysis of Anti-Cancer Chemicals 2017-2022 IDIQ for release analysis of anti-cancer drug bulk lots.
The order covers analytical chemistry work including appearance assessment, polymorphic form determination, infrared spectroscopy, high-performance liquid chromatography assay and impurity analysis, moisture determination, residual solvent testing, refractive index measurement, and heavy metals analysis on two bulk drug lots designated NSC 706744. Place of performance is Menlo Park, CA. The period of performance runs from February 24, 2020 through September 30, 2020. The contract is priced on a cost-plus-fixed-fee basis with no set-aside applied.
Description
This requirement is to perform the release analysis (appearance, PMR, IR, hplc* (assay; impurity), moisture, residual solvents, ROI and heavy metals) of 2 bulk drug lot of NSC 706744. POP is 2/24/2020-9/30/2020.
Quick answers
Who was awarded contract 75N91020F00002?
75N91020F00002 was awarded to Sri International by National Cancer Institute (National Institutes of Health) on February 24, 2020.
How much is contract 75N91020F00002 worth?
The government has obligated $35,253 on 75N91020F00002.
Is contract 75N91020F00002 an order under another contract?
Yes. 75N91020F00002 is a delivery order under HHSN261201700014I, an indefinite delivery contract, on NIH Analysis of Anti-Cancer Chemicals 2017-2022.
Was contract 75N91020F00002 competed?
The extent of competition for 75N91020F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award